CatchMe Theraputics
Precision Medicine for Epitranscriptome Machinery
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in August 2021 by Yael Tsalenchuck, CatchMe Theraputics operates with 1–10 employees. The company has secured funding across one round from one investor, FutuRx, which participated in its Pre-Seed round in December 2021.
Business overview
CatchMe Theraputics is a Health Tech & Life Sciences company focused on developing precision medicine solutions. The company's core technology involves specific inhibition based on the in vivo biological binding preference of targeted proteins, with a versatile platform designed to target various methyl binding proteins and indications. CatchMe Theraputics serves the pharmaceuticals and biotechnology markets, operating within the Drugs Discovery & Development sector.
Log in to access full profile ›Company Intelligence Q&A
- When was CatchMe Theraputics founded?
- CatchMe Theraputics was founded in August 2021.
- Who is a founder of CatchMe Theraputics?
- Yael Tsalenchuck is a founder of CatchMe Theraputics.
- What is CatchMe Theraputics' primary focus?
- CatchMe Theraputics focuses on precision medicine for epitranscriptome machinery, developing solutions for specific inhibition based on the in vivo biological binding preference of targeted proteins.
- What is the company's employee count?
- CatchMe Theraputics has 1–10 employees.
- Which investor participated in CatchMe Theraputics' Pre-Seed round?
- FutuRx participated in CatchMe Theraputics' Pre-Seed funding round in December 2021.